NICE flip-flops on Esbriet and Revolade
This article was originally published in Scrip
Executive Summary
NICE, the UK's health technology appraisal body, has made a U-turn on previous decisions and is now recommending both Intermune's Esbriet (pirfenidone) and GlaxoSmithKline's Revolade (eltrombopag).
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.